Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: BRRY) ("DelMar") today announced the successful acquisition (the "Acquisition"), through a share exchange agreement, of all of the outstanding shares of Del Mar Pharmaceuticals (BC) Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer.  Concurrent with the Acquisition, DelMar completed the first closing in a private placement consisting of approximately 6.7 million units of its securities to qualified accredited investors, for total gross proceeds of approximately $5.4 million.

DelMar will be quoted on the OTC QB under the symbol "BRRY" beginning January 25th, 2013; the symbol will be changed to "DMPI" on or about January 31, 2013.

Charles Vista LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.

"DelMar is pleased to achieve this important milestone," stated Jeffrey Bacha , Chief Executive Officer of DelMar. "Becoming a publicly traded company will allow for broad and diversified investor exposure and access to the capital markets.  These funds will position us to expand and accelerate our drug development activities with our lead drug candidate, VAL-083.  Our company and our management are committed to creating shareholder value by executing on our mission to rapidly develop and commercialize proven cancer therapies in new orphan drug indications in areas of significant unmet medical need, particularly where patients have failed modern targeted medicines."

VAL-083, represents a "first in class" small-molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  InterMune, Inc. (NASDAQ: ... its second quarter 2014 financial results at the close ... live conference call and webcast will be hosted by ... Interested investors and others may participate in ... 212-231-2900 (international), conference ID#21728775. A replay of the webcast and ...
(Date:7/28/2014)... Muncie, IN (PRWEB) July 28, 2014 ... Aeromodeling Center, in Muncie IN, is pleased to announce ... by the National Museum of the United States Air ... than a year-long process that concluded this spring with ... for the Dayton, OH museum. , The National ...
(Date:7/25/2014)... Calif. , July 25, 2014 Amgen ... of Directors today declared a $0.61 per share dividend ... be paid on Sept. 5, 2014, to all stockholders ... Aug. 14, 2014.  About Amgen Amgen ... patients suffering from serious illnesses by discovering, developing, manufacturing ...
(Date:7/25/2014)... 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... Metabolomics or Metabonomics is the scientific study of ... new experimental technique that is being widely used ... are small molecules that are present in blood, ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... College (CVTC) will receive a $500,000 grant from ... nanotechnology incubator on their Gateway Manufacturing Technology Center in ... systems at the scale of the atom. , ,"Through ... nanotechnology industry can grow, expand, and reach its full ...
... Wis. Small Tree Communications , a ... announced its 10Gb Ethernet solution for Apples Xserve G5. ... Mac OS X Server 10.4 Tiger, the company claims ... ,In addition to proprietary networking drivers, Small Trees solution ...
... Medical imaging software developer Cedara Software and ... for Kodak to offer Cedara B-CAD to its customers ... CARESTREAM Mammography Workstation. , ,Cedara B-CAD is a Computer ... of breast lesions using ultrasound images, providing tools for ...
Cached Biology Technology:
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
(Date:7/27/2014)... have discovered a new species of mayfly in the southern ... India. In fact, this is the first time that any ... collected in peninsular India. , The new species, called ... Soldan for his substantial contribution to the understanding of the ... of a study that describes the new mayfly in the ...
(Date:7/27/2014)... have shown the potential for global climate change to ... most part, ignored the interactions between increasing temperature and ... to damage crops. , A new study involving researchers ... significant, suggesting that policymakers need to take both warming ... , The study looked in detail at global production ...
Breaking Biology News(10 mins):Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... ORLEANSAlzheimer,s disease (AD) is a tragic disease that robs an individual ... the age of 65 now suffer from the disease and one ... to popular belief, Alzheimer,s does not only affect the elderly. Familial ... young as 30. The Study , Alzheimer,s ...
... for adults, teens, and youngsters. It is less clear ... growth during gestation. Now that scientists have determined that, ... a fetus, studies are underway to examine the mother/fetus/exercise/health ... Entitled The Effects of Maternal Exercise on Fetal Breathing ...
... of people around the world, causing numerous problems ranging ... issues. Initial drug use can be motivated by curiosity ... rats, it can also be the result of a ... new study examines the impact of social isolation on ...
Cached Biology News:Computational model examines the pathways of Alzheimer's that strikes at the young 2Effects of maternal exercise on fetal breathing movements 2Early isolation linked to enhanced response to cocaine 2
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
... Reverse Transcriptase is a recombinant Moloney ... MultiScribe Reverse Transcriptase is similar to ... its recommended usage. MuLV reverse transcriptase ... that uses single-stranded RNA as a ...
Biology Products: